Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Fallypride

From Wikipedia, the free encyclopedia
Fallypride (18F)
Clinical data
Pregnancy
category
  • N/A
ATC code
  • none
Legal status
Legal status
  • Research compound
Identifiers
  • 5-(3-18F-fluoropropyl)-2,3-dimethoxy-N-[(2S)-1-prop-2-enylpyrrolidin-2-yl]methyl]benzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H29FN2O3
Molar mass364.461 g·mol−1
3D model (JSmol)
  • COC1=CC(=CC(=C1OC)C(=O)NC[C@@H]2CCCN2CC=C)CCCF
  • InChI=1S/C20H29FN2O3/c1-4-10-23-11-6-8-16(23)14-22-20(24)17-12-15(7-5-9-21)13-18(25-2)19(17)26-3/h4,12-13,16H,1,5-11,14H2,2-3H3,(H,22,24)/t16-/m0/s1
  • Key:OABRYNHZQBZDMG-INIZCTEOSA-N

Fallypride is a high-affinity dopamine D2/D3 receptor antagonist used in medical research,[1] usually in the form of fallypride (18F) as a positron emission tomography (PET) radiotracer in human studies.[2][3]

References

[edit]
  1. Mukherjee J, Yang ZY, Das MK, Brown T (April 1995). "Fluorinated benzamide neuroleptics  III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer". Nuclear Medicine and Biology. 22 (3): 283–96. doi:10.1016/0969-8051(94)00117-3. PMID 7627142.
  2. Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, Mantil J (December 2002). "Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors". Synapse. 46 (3): 170–88. doi:10.1002/syn.10128. PMID 12325044. S2CID 24852944.
  3. Rieck RW, Ansari MS, Whetsell WO, Deutch AY, Kessler RM (February 2004). "Distribution of dopamine D2-like receptors in the human thalamus: autoradiographic and PET studies". Neuropsychopharmacology. 29 (2): 362–72. doi:10.1038/sj.npp.1300336. PMID 14627996.